A Low Dose Remifentanil Infusion During Tracheal Extubation in Surgical Intensive Care Unit Patients
Information source: Severance Hospital
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Tracheal Extubation
Intervention: Remifentanil (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Severance Hospital
Summary
Tracheal extubation can be associated with hyperdynamic circulatory response. The
investigators examined the effect of maintaining a remifentanil infusion on the
cardiovascular response during extubation in propofol-remifentanil sedated patients after
surgery.
Clinical Details
Official title: A Low Dose Remifentanil Infusion During Tracheal Extubation in Surgical Intensive Care Unit Patients
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
Primary outcome: Cardiovascular response during extubation
Secondary outcome: Time of awake and extubation
Eligibility
Minimum age: 20 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
1. Age ≥ 20
2. Short term ventilator care after surgery in intensive care unit
Exclusion Criteria:
1. pneumonia
2. chronic obstructive lung disease
3. asthma
4. end stage renal disease
5. risk factors for aspiration
Locations and Contacts
Department of Anesthesiology and Pain Medicine and Anesthesia and Pain Research Institute, Yonsei University College of Medicine, Seoul 120-752, Korea, Republic of
Additional Information
Starting date: May 2010
Last updated: March 10, 2011
|
